A Study of LY3200882 in Participants With Solid Tumors
About the study
The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- The participant must have histological or cytological evidence of cancer.
- Have adequate organ function.
- Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1.
- Are able to swallow capsules and tablets.
EXCLUSION CRITERIA
Exclusion Criteria:
- Have moderate or severe cardiovascular disease.
- Have a serious concomitant systemic disorder.
- Have acute leukemia.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Solid Tumor
Age (in years)
18+
Phase
Phase 1
Participants needed
223
Est. Completion Date
Aug 1, 2024
Treatment type
Interventional
Sponsor
Eli Lilly and Company
ClinicalTrials.gov identifier
NCT02937272
Study number
I8X-MC-JECA
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?